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Body mass indexAbstract Background: Chronic Obstructive Pulmonary Disease (COPD) is characterized by per-
sistent airﬂow limitation that is usually progressive leading to disability with an increasing burden
to the patient, his family and to the health services. Pulmonary rehabilitation (PR) is used as a com-
plementary evidence-based effective treatment option for patients with COPD. This study was car-
ried out to evaluate the effects of PR on the rate of forced expiratory volume in 1 second (FEV1)
decline in patients with stable COPD.
Patients and methods: Eighty ﬁve COPD patients completed the study, 60 with a mean age of
63 ± 7 years underwent PR for 3 years and 25 with a mean age of 62 ± 5.4 received only pharma-
cological treatment according to guidelines. Pulmonary function testing and body mass index
(BMI) were carried out for all patients upon enrollment and at 1 year intervals for 3 years.
Results: The FEV1 decreased from 1246.8 ml (46.9% of predicted value) to 1192.8 ml (44.8% of
predicted) in the PR group, while in the control group the FEV1 decreased from 1224.6 ml (45.4%
of predicted) to 1060 ml (39.3% of predicted) (i.e., FEV1 declined 54 ml versus 164.6, respectively,
p= 0.008). Also, the PR group showed an improvement in BMI, while in the control group a
decreased BMI was noticed (p= 0.001).
Conclusion: Pulmonary rehabilitation resulted in slowing down the decline in FEV1, as well as
improving BMI in patients with stable COPD.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. All rights reserved.Introduction
Chronic Obstructive Pulmonary Disease (COPD) is character-
ized by persistent airﬂow limitation that is usually progressived.
42 S. Embarak et al.leading to disability with an increasing burden to the patient,
his family and to the health services [1]. The most commonly
used lung function parameter is the forced expiratory volume
in 1 second (FEV1), the decline of which is estimated to be
47–79 ml/year in COPD patients as compared to 30 ml/year
in healthy subjects [2–7]. Smoking cessation has been shown
to be the only effective intervention to alter the rate of decline
in FEV1 in patients with COPD [2,8,9]. However, two recent
large placebo-controlled trials have shown that such a result
can be also obtained with an appropriate pharmacotherapy
[10,11].
Pulmonary rehabilitation (PR) is used as a complementary
evidence-based effective treatment option for patients with
COPD. It has been recognized to improve symptoms, exercise
tolerance and quality of life in those patients [12,13]. However,
the effects of PR on lung function have been poorly investi-
gated [14–16]. Moreover, one of the major unresolved issues
is the duration of treatment. For example, outpatient exercise
training with two or three weekly sessions for 4 weeks showed
less beneﬁt than similar training for 7 weeks [17–19]. Hence,
the present study was carried out to evaluate the effects of
three years pulmonary rehabilitation on the rate of FEV1
decline and the change of body mass index (BMI) in patients
with stable COPD.
Patients and methods
Patients
This study was carried out in Respiratory and Rheumatology
Departments and Outpatient Clinics during the period from
August 2010 through March 2014. It included COPD patients
diagnosed and under pharmacological treatment according to
the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines [1]; supported by spirometric evidence of
airﬂow obstruction (forced expiratory volume in one second
(FEV1)/forced vital capacity (FVC) <0.70) when clinically sta-
ble. We excluded patients who were active smokers or had quit
smoking less than 2 years prior to the onset of this study,
patients with chronic respiratory failure requiring long-term
oxygen therapy and those in whom there were other major
medical problems such as heart failure, myocardial infarction,
cerebrovascular disease, cancer, neuromuscular, or severe
orthopedic disorders. Also, patients who had an acute exacer-
bation in the 4 weeks before the enrollment (i.e., requiring
antibiotics, oral/parenteral steroids, oxygen or increased bron-
chodilators dosage) were excluded.
Methods
All patients underwent pulmonary function test according to
ATS/ERS [20] recommendations, upon enrollment and at 1-
year intervals up to 3 years using the Zan-100 (Flow Handy
II) pulmonary function apparatus. Forced vital capacity
(FVC) and forced expiratory volume in 1 second (FEV1) were
measured. The post-bronchodilator values were used for statis-
tical analysis. BMI (kg/m2) was measured for each patient and
was re-calculated at every spirometry.
PR program was carried out in groups of 6–8 patients
according to Riario-Sforza et al. [21]. It involved a schedule
of 12 sessions in a 6-week period and included: (1) exercisetraining using a treadmill for 30 min; (2) upper-limb and trunk
exercise training, with warm-up and limbering exercises
focused on arm, shoulder and trunk muscle groups for
30 min. Exercise intensity was graded, as the patient pro-
gressed in the PR program. In addition, patients attended a
COPD education course, and were instructed on how to per-
form muscle exercises and respiratory training daily at home
for the entire duration of the program. The PR cycle was
repeated every 6 months for a duration of 3 years.
Statistical analysis
Statistical analysis was performed with Epi Info version 7
and SPSS version 19 statistical software package (SPSS Inc.,
Chicago, IL, USA). Data are presented as mean ± SD. Anal-
ysis of variance (ANOVA) was used to compare between the
groups for the analysis of the entire 3 year period. For time
point differences, a two-sample t test was used. p-Value
<0.05 was considered signiﬁcant.
Results
First, this study included 95 COPD patients, 67 of them agreed
to receive PR (PR group) and 28 did not require and received
pharmacotherapy only (control group). Ten patients, 10.5%
withdrew during the observation period (7 in the PR group
and 3 in the control group). So, ﬁnally 85 patients completed
the present study (60 in the PR group with a mean age of
63 ± 7 and 25 in the control group with a mean age of
62 ± 5.4) and their demographic data are shown in Table 1.
Table 2 shows body mass index (BMI) changes in the stud-
ied groups over 3 years. The PR group showed an improve-
ment in BMI, while in the control group a decreased BMI
was noticed (p= 0.001).
Table 3 & Fig. 1 shows FEV1 values over 3 years in the
studied population. In the PR group, the FEV1 decreased from
1246.8 ml (46.9% of predicted value) to 1192.8 ml (44.8% of
predicted), while in the control group the FEV1 decreased from
1224.6 ml (45.4% of predicted) to 1060 ml (39.3% of pre-
dicted) (i.e., FEV1 decline of 54 ml versus 164.6, respectively,
p= 0.008).
Discussion
To date, none of the existing medications for COPD has been
shown conclusively to modify the long-term decline in lung
function that is the hallmark of this disease [1]. Pulmonary
rehabilitation (PR) is used as a complementary treatment
option for these patients [16]. The American Thoracic Society
(ATS) and the European Respiratory Society (ERS) published
a statement, in which PR was recognized as an evidence-based,
multidisciplinary and comprehensive intervention for patients
with chronic respiratory diseases who are symptomatic and
often have decreased daily life activities [12]. However, little
data are available about the effects of PR on pulmonary func-
tion in patients with stable COPD. So, the aim of the current
work was to investigate the effects of PR over 3 years on lung
function of COPD patients.
Results of the present study illustrated that three years of
PR program for COPD patients resulted in a signiﬁcant lower
decline in FEV1 compared to patients in the control group who
Table 1 Demographics of all studied patients.
Parameter PR (no = 60) Control (no = 25) p-Value
Age, mean ± SD 63 ± 7 62 ± 5.4 0.52
Sex: M/F 47/13 17/8 0.41
Smoking history (pack/year) 49 ± 27 52 ± 29 0.65
BMI, kg/m2 24.5 ± 0.9 24.8 ± 0.8 0.15
Exacerbations (no in year before study) 1.2 ± 1.5 0.9 ± 1.3 0.39
FEV1/FVC 0.57 ± 0.08 0.56 ± 0.09 0.61
FEV1 % pred. 47 ± 6 45 ± 4 0.50
Medications, no (%)
Inhaled glucocorticoids 41 (68.3%) 19 (76%) 0.64
Long acting beta agonist 46 (76.7%) 21 (84%) 0.57
Tiotropium 23 (38.3%) 11 (44%) 0.64
PR: pulmonary rehabilitation; M: male; F: female; BMI: body mass index; FVC: forced vital capacity; FEV1: forced expiratory volume in 1
second.
Table 2 Effect of pulmonary rehabilitation on body mass index.
BMI PR (no = 60) Control (no = 25) F p-Value
Basal BMI 24.5 ± 0.9 24.8 ± 0.8 12.98 0.001
BMI after 1 year 24.9 ± 1.1 24.1 ± 0.9
BMI after 2 years 25.3 ± 1.1 23.8 ± 1.1
BMI after 3 years 25.2 ± 1.3 23.3 ± 1.3
PR: pulmonary rehabilitation; BMI: body mass index.
Table 3 Effect of pulmonary rehabilitation on FEV1.
FEV1 (ml) PR (no = 60) Control (no = 25) F p-Value
Basal FEV1 1246.8 ± 149 1224.6 ± 107.2 7.49 0.008
FEV1 after 1 year 1226.5 ± 148.4 1151.8 ± 114
FEV1 after 2 years 1210.1 ± 141.5 1099.4 ± 70.8
FEV1 after 3 years 1192.8 ± 136.3 1060 ± 73.6
FEV1: forced expiratory volume in 1 second; PR: pulmonary rehabilitation.
Figure 1 Evolution of forced expiratory volume in 1second
(FEV1) over 3 years in COPD patients who received pulmonary
rehabilitation (PR) compared to patients on pharmacological
treatment only (control).
Effects of PR on FEV1 43received pharmacotherapy only (54 ml versus 164.4 ml, respec-
tively, p= 0.008), as the FEV1 decreased from 1246.8 ml
(46.9% of predicted value) to 1192.8 ml (44.8% of predicted)
in the PR group, whereas in the control group the FEV1decreased from 1224.6 ml (45.4% of predicted) to 1060 ml
(39.3% of predicted). Also, the PR group showed an improve-
ment in BMI, while in the control group a decreased BMI was
noticed (p= 0.001). The above mentioned results are in accor-
dance with that obtained by Stav et al. [16] who studied 80
patients with moderate to severe COPD and also found a
lower decline in FEV1 after 3 years in the patients who received
PR compared to controls (74 ml versus 149 ml), but a mild
improvement in BMI was noticed in the PR group versus
decrease in the control group.
Also, in accordance PR was shown able to slow down the
FEV1 decline in previous studies [14,15]. Cote and Celli [14]
found in a group of 116 patients who received PR a mean
decline of 20 ml over 2 years compared to 160 ml decline in
130 controls. Such patients were deﬁned as assuming optimal
medical therapy, but the treatment details were not described
[16]. In 2007, another study showed a mean FEV1 decline of
18 ml/year in 48 PR treated patients over 7 years, but without
a control group [15].
In contrary, Incorvaia et al. [22] studied 257 COPD patients
and found that FEV1 in the PR group, increased from 1240 ml
(57.3% of predicted) to 1252.4 ml (60.8%) after 3 years,
whereas in the controls the values were 1367 ml (55% of
44 S. Embarak et al.predicted) at baseline and 1150 ml (51%) after 3 years. This dis-
crepancy in results between the present study and that of Incor-
vaia et al. could be attributed to the selection criteria of the
studied patients being with more severe airﬂow limitation in
this study (FEV1 47% of predicted in the PR group and 45%
in the controls) compared to their study (57.3% and 55%).
It was speculated that participating in the pulmonary reha-
bilitation program, over a considerably long period, increased
in incremental stages small airways function and/or recruit-
ment. In addition, the exercise regimen likely improves secre-
tion evacuation, which can reduce airway infection/
inﬂammation and decrease COPD exacerbations [16]. More-
over, Petersen and Pedersen [23] noted that regular exercise
protected against diseases associated with chronic inﬂamma-
tion, which is crucial in the pathogenesis of COPD. The contri-
bution of PR in the slowing of FEV1 decline adds an
additional beneﬁcial effect of pulmonary rehabilitation for
COPD patients. FEV1 decline may serve as a predictor of
death from COPD, and therefore PR could be considered as
a disease modiﬁer [16,24].
Regarding BMI, it was previously described to be an effec-
tive indicator of prognosis in COPD, with a clear association
between decreasing body mass and increasing mortality [25–
28], whereas available data indicate that those patients able
to gain weight improve their prognosis [27,29]. In the current
work, the signiﬁcant improvement in BMI which was observed
among COPD patients who received PR, may affect the prog-
nosis of those patients, a point that needs further study.
In conclusion, three years of pulmonary rehabilitation was
able to slow down the decline in FEV1 and to improve BMI in
patients with stable COPD.
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